SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-041185
Filing Date
2023-11-14
Accepted
2023-11-14 16:34:46
Documents
61
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1142131
2 ex31-1.htm EX-31.1 18568
3 ex31-2.htm EX-31.2 17917
4 ex32-1.htm EX-32.1 8022
  Complete submission text file 0001493152-23-041185.txt   6136848

Data Files

Seq Description Document Type Size
5 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zvsa-20230930.xsd EX-101.SCH 52543
6 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT zvsa-20230930_cal.xml EX-101.CAL 52032
7 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zvsa-20230930_def.xml EX-101.DEF 242964
8 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zvsa-20230930_lab.xml EX-101.LAB 411174
9 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zvsa-20230930_pre.xml EX-101.PRE 317034
55 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 934122
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41184 | Film No.: 231407160
SIC: 2834 Pharmaceutical Preparations